Skip to main content

Dr. Stephen Ong, MD

Family Medicine (Family Medicine Physician)

6357 Oxon Hill Rd
Oxon Hill, MD 20745

Who else practices at this address →

Prince George's County includes primary care (19% of residents) and mental health (13% of residents) shortage areas. About shortage areas

Call (301) 839-2700

  • Medicare participating

At a glance

Years since graduation
56
In the NPI registry since
2006
Medicare patients seen, 2024
197

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Family Medicine Physician primary
    MD license D014760
  • Surgery Physician
    DC license MD6423

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Family Medicine per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
197
Services billed
1,348
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes292163
Annual alcohol misuse screening, 5 to 15 minutes144144
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit139139
Established patient office or other outpatient visit, 20-29 minutes13999
Annual depression screening, 5 to 15 minutes119119
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report117110
Advance care planning, first 30 minutes8482
Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage6060
Administration of influenza virus vaccine6060
Assessment of and care planning for patient with impaired thought processing, typically 60 minutes4141

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 11 companies reported 40 payments worth $3,824 in total to this clinician.

By type
Travel and Lodging$2,261
Food and Beverage$1,563

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 23, 2025Amgen Inc.
Jul 23, 2025
Travel and Lodging
travel to Dallas, TX · in-kind
$613
Feb 28, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Feb 28, 2025
Travel and Lodging
travel to Fort Lauderdale, FL · in-kind
$563
Feb 10, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Feb 10, 2025
Travel and Lodging
travel to Fort Lauderdale, FL · in-kind
$514
Jul 23, 2025Amgen Inc.
Jul 23, 2025
Travel and Lodging
travel to Dallas, TX · in-kind
$375
Mar 18, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Mar 18, 2025
Travel and Lodging
travel to Fort Lauderdale, FL · in-kind
$140
Mar 31, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Mar 31, 2025
Travel and Lodging
travel to Fort Lauderdale, FL · in-kind
$56.53

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Maryland →

Industry-funded research

Named as a principal investigator on 15 industry-funded studies in 2025, from 11 companies. The companies reported $1,135,840 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A phase 3 randomized placebocontrolled observerblinded trial to evaluate the safety of a 6VALENT ospabased lyme disease vaccine VLA15 in healthy children 5 through 17 years of age
    Pfizer Inc.
  • A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
    Vertex Pharmaceuticals Incorporated
  • Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
    Novartis Pharmaceuticals Corporation
  • A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
    Eli Lilly and Company · Completed · NCT04255433
  • A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
    Amgen Inc.
  • A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension
    Novartis Pharmaceuticals Corporation
  • A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
    AstraZeneca Pharmaceuticals LP
  • A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
    Boehringer Ingelheim Pharma GmbH & Co.kg
  • A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Family Medicine clinicians in Oxon Hill

Sources

NPI registry (CMS NPPES, November 2026; record last updated May 10, 2011), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1851479281. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.